中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢乙肝抗病毒的个体化治疗

池肇春

引用本文:
Citation:

慢乙肝抗病毒的个体化治疗

详细信息
  • 中图分类号: R512.62

Individualized antiviral therapy for chronic hepatitis B


  • 摘要:

    <正>目前用于慢乙肝抗病毒治疗的药物分两大类,即核苷类和核苷类似物(NUCs)及干扰素(IFN)共计7种药,即拉米夫定、阿德福韦酯、替比夫定、恩替卡韦、替诺福韦、普通干扰素、聚乙二醇干扰素α-

     

  • [1]Wilt TJ, Shamliyan T, Shaukat A, et al.Management of chronic hepa-titis B[J].Evid Rep Technol Assess (Full Rep) , 2008, (174) ∶1-671.
    [2]Terrault NA.Benefits and risks of combination therapy for hepatitis B[J].Hepatology, 2009, 49 (5suppl) ∶S122-128.
    [3]Sung JJ, Tsoi KK, Wong VW, et al.Meta-analysis:Trearment of hepatitis B infection reduces risk of hepatocellular carcinoma[J].Al-iment Pharmacol Ther, 2008, 28 (9) ∶1067-1077.
    [4]Wong GL, Wong VW, Choi PC, et al.Evaluation of alanine transami-nase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography[J].Am J Gastroenterol, 2008, 103 (12) ∶3071-3081.
    [5]Morgan M, Keeffe EB.Diagnosis and treatment of chronic hepatitis B:2009update[J].Minerva Gastroenterol Dietol, 2009, 55 (1) ∶5-22.
    [6] 金清龙译, 牛俊奇审校.《2009EASL乙肝诊治指南》[N].中国医学论坛报, 2009-04-16 (2) .
    [7] 金清龙译, 牛俊奇审校.《2009EASL乙肝诊治指南》[N].中国医学论坛报, 2009-05-7 (3) .
    [8]Guo Y, Li Y, Mu S, et al.Eviolence that methylation of hepatitis B vi-rus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication[J].J Med Virol, 2009, 81 (7) ∶1177-1183.
    [9]Lu HY, Zhuang LW, Yu YY, et al.Effects of antiviral agents on in-trahepatic cccDNA Iin HBeAg-positive chronic hepatitis B patients[J].Zhonghua Gan Zang Bing Za Zhi, 2008, 16 (3) ∶198-202.
    [10]Moucari R, Mackiewicz V, Leda O, et al.Early serum HBsAg drop:a strong predictoy of sustained viyological response to pegylated inter-feron alfa-2a in HBeAg-negative patients[J].Hepatology, 2009, 49 (4) ∶1151-1157.
    [11]Hass HG, Bock T, Nehls O, et al.Rapid HBV DNA decrease (week12) is a important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B[J].J Gastroenterol, 2009, 21.[Epub ahead of print].
    [12]Leung N, Peng CY, Hann HW, et al.Early hepatitis B virus DNA re-duction in hepatitis B e aantigen-positive patients with chronichepa-titis B:A randomized international studyof entecavir versus adefovir[J].Hepatology, 2009.49 (1) ∶72-79.
    [13]Madan K, Batra Y, Jha jk, et al.Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection[J].Trop Gastroen-terol, 2008, 29 (2) ∶59-61.
    [14]Lampertico P, Colombo M.HBeAg-negative chronic hepatitis B:why do I treat my patients with nucleos (t) ide analogues[J].Liver Int, 2009, 29 (Suppl1) ∶130-132.
    [15]Papadopoulos VP, Chrysagis DN, Protopapas AN, et al.Peginterferon alfa-2b as monotherapy or in combination with lamivudine in pa-tients with HBeAg-negative chronic hepatitis B:a randomized study[J].Med Sci Monit, 2009, 15 (2) ∶CR56-61.
  • 加载中
计量
  • 文章访问数:  2147
  • HTML全文浏览量:  2
  • PDF下载量:  1053
  • 被引次数: 0
出版历程
  • 出版日期:  2010-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回